The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells
- PMID: 3928557
The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells
Abstract
Highly purified recombinant human interferon-gamma produced by Escherichia coli (ReIFN-gamma) was examined for ability to stimulate natural killer (NK) cell cytotoxic activity and antibody-dependent cell-mediated cytotoxicity in human peripheral blood lymphocytes (PBLs) in comparison with natural human interferon-gamma (IFN-gamma) and with recombinant human interferon-beta produced by E. coli (ReIFN-beta). The activity of ReIFN-gamma to stimulate NK cell cytotoxicity was about 10 times greater than that of ReIFN-beta and similar to that of IFN-gamma when PBLs were pretreated with each interferon for 16 hr. The effects of ReIFN-gamma were completely neutralized by a rabbit anti-ReIFN-gamma antibody, but not by a rabbit anti-ReIFN-beta. ReIFN-gamma did not show any significant NK-enhancing effect when it was added directly to the killing phase of standard 51Cr-release assay for 4 hr, while ReIFN-beta showed a marked effect. The time course study showed that the NK-activating effect of ReIFN-gamma was not expressed until 2 hr after the start of incubation, while that of ReIFN-beta was expressed rapidly and sufficiently within 15 min. This kinetic difference between ReIFN-gamma and ReIFN-beta was confirmed by an experiment using the Ca2+-pulse method, in which the killing rate in the Ca2+-dependent stage of NK cytolysis was increased by ReIFN-gamma, but only after 6 hr of preincubation, while the effect by ReIFN-beta was expressed rapidly at 30 min. These findings suggest that ReIFN-gamma and ReIFN-beta may stimulate NK cell cytotoxicity through different intracellular events after they bind to their receptors on the surface of NK cells.
Similar articles
-
Immune-enhancing effect of recombinant human interferon-beta produced in Escherichia coli on human peripheral blood mononuclear cells in vitro.Gan. 1983 Oct;74(5):743-50. Gan. 1983. PMID: 6357933
-
Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.J Immunol. 1986 Feb 1;136(3):1117-22. J Immunol. 1986. PMID: 3079797
-
Differential effects of recombinant human interferon-gamma and interleukin 2 on natural killer cell activity of peripheral blood in early human development.J Immunol. 1985 Jul;135(1):180-4. J Immunol. 1985. PMID: 3923100
-
NK cells and interferons.Cytokine Growth Factor Rev. 2015 Apr;26(2):113-20. doi: 10.1016/j.cytogfr.2014.11.003. Epub 2014 Nov 13. Cytokine Growth Factor Rev. 2015. PMID: 25443799 Review.
-
[Protein A: an immunomodulator in cancer patients].Rev Med Univ Navarra. 1988 Jul-Sep;32(3):163-8. Rev Med Univ Navarra. 1988. PMID: 3070688 Review. Spanish.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous